|
pubmed:abstractText |
For patients with a normal coagulation system, who experience serious bleeding, sound evidence for recombinant activated factor VII (rFVIIa) as an effective haemostatic agent is only scarcely available so far from controlled clinical trials. In systematic reviews on the clinical use of rFVIIa, treatment failures were only rarely reported.
|
|
pubmed:affiliation |
2nd Division of Internal Medicine, Department of Medicine, Central Hospital of Bolzano, Lorenz Boehler Street 5, I-39100 Bolzano (BZ), Italy. christian.wiedermann@uibk.ac.at.
|
